Effect of Green Tea Extract on Type 2 Diabetes

Effect of Green Tea Extract on Type 2 Diabetes: a Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Status

Completed

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00567905

Acronym

GTT-DM

Enrollment

Registered

2007-12-05

Start date

2007-09-30

Completion date

2008-08-31

Last updated

2009-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Keywords

Type 2 Diabetes, Green tea extract, overweight

Brief summary

The purpose of this study is to examine the effect of green tea extract (GTE) on type 2 diabetes and to explore the relationship between GTE and related hormone peptides.

Detailed description

Green tea is one of the most popular beverages in the world. It is believed to have beneficial effects in prevention and treatment of many diseases, one of which is anti-obesity and anti-diabetes. The benefit effects of green tea are mainly attributed to its polyphenol content, especially the most abundant one-epigallocatechin gallate (EGCG), which might inhibit adipocyte proliferation and differentiation in vitro studies We hypothesized that GTE would improve insulin resistance in type 2 overweight diabetes and related hormone peptides will be influenced. Thus, we conducted this randomized clinical trial to examine the effect of GTE on type 2 diabetes and to explore the relationship between GTE and related hormone peptides.

Interventions

DIETARY_SUPPLEMENTGreen tea extract

main content is epigallocatechin gallate (EGCG, 58%)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

20 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Type 2 diabetes * Body mass index \>25 kg/mm * Aged between 20 and 65 years * Being Chinese

Exclusion criteria

* Aminotransferases aspartate or aminotransferases alanine \> 80 IU/L, serum creatinine \> 2.0 mg/dl, * Prolating or pregnant women, and patients with heart failure, acute myocardiac infarct, stroke and heavy injuries, and * Any other conditions not suitable for trial as evaluated by the physician.

Design outcomes

Primary

Measure	Time frame
Homeostasis model assessment for insulin resistance (HOMA-IR) was used as the major outcome measurement.	16 weeks

Secondary

Measure	Time frame
HbA1C, blood sugar, creatinine, aminotransferases aspartate, aminotransferases alanine, uric acid, and plasma lipoproteins (triglyceride, cholesterol, cholesterol-HDL (HDL) and cholesterol-LDL (LDL)) cholesterol; BMI,WC---.	16 weeks

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 9, 2026